Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
07/2003
07/03/2003WO2003053954A1 Benzothiophenes as adenosine receptor modulators
07/03/2003WO2003053948A1 Isochroman compounds for treatment of cns disorders
07/03/2003WO2003053947A1 Benzothia(dia)zine derivatives and their use as ampa modulators
07/03/2003WO2003053946A1 7-amino-benzothiazole derivatives as adenosine receptor ligands
07/03/2003WO2003053945A2 Urea derivatives and their use as vanilloid receptor antagonists
07/03/2003WO2003053944A1 Pancreatic lipase inhibitor compounds, their synthesis and use
07/03/2003WO2003053942A1 Aryloxyphenyl and arylsulfanylphenyl derivatives
07/03/2003WO2003053939A1 Benzimidazole derivatives and their use as gnrh antagonists
07/03/2003WO2003053938A1 Benzimidazols and indols as glucagon receptor antagonists/inverse agonisten
07/03/2003WO2003053933A1 Heteroaryl-substituted aminocyclohexane derivatives
07/03/2003WO2003053930A1 1,4-dihydro-1,4-diphenylpyridine derivatives
07/03/2003WO2003053928A1 Serotonine reuptake inhibitor
07/03/2003WO2003053927A1 Piperazine derivative
07/03/2003WO2003053926A1 Novel phenylalanine derivative
07/03/2003WO2003053925A1 Pyrrolidine-2-ones as factor xa inhibitors
07/03/2003WO2003053923A2 Pyrrolidine derivatives as prostaglandin modulators
07/03/2003WO2003053922A2 Heteroaryl substituted imidazole modulators of metabotropic glutamate receptor-5
07/03/2003WO2003053919A1 Substituted cyclohexane derivatives
07/03/2003WO2003053915A2 Compounds for the treatment of inflammatory disorders
07/03/2003WO2003053912A1 α-(N-SULPHONAMIDO)ACETAMIDE DERIVATIVES AS β-AMYLOID INHIBITORS
07/03/2003WO2003053911A1 Acetyl l-carnitine salt with a dicarboxilic organic acid and process for preparing same
07/03/2003WO2003053565A1 Adsorbent for phosphoric acid
07/03/2003WO2003053522A1 Methods of treating bacterial infections in dogs and cats
07/03/2003WO2003053501A1 Metered dose inhaler
07/03/2003WO2003053480A1 Composition for treating contact lenses in the eye
07/03/2003WO2003053473A2 Ph-sensitive polymeric conjugates of an anthracycline drug
07/03/2003WO2003053469A1 Methods to reduce body fat
07/03/2003WO2003053466A1 Skin barrier function repair accelerators
07/03/2003WO2003053462A2 Staphylococcus aureus exopolysaccharide and process
07/03/2003WO2003053457A1 Polypeptide, the conjugate thereof containing doxorubicine and a pharmaceutical composition based thereon
07/03/2003WO2003053456A1 Use of hyperforin or st john's wort extracts against anaphylactic states of shock and for maintaining and improving bone health
07/03/2003WO2003053455A1 Surfactant prevention of lung complications from cancer chemotherapy
07/03/2003WO2003053454A1 Compositions incorporating (-)-hydroxycitric acid, chromium, and gymnemic acid, and related methods for promoting healthy body weight and improving related health factors
07/03/2003WO2003053453A1 Improvements in or relating to liquid, eye-instillable preparations comprising sodium hyaluronate
07/03/2003WO2003053452A1 Heparin-containing ophthalmic agent
07/03/2003WO2003053451A1 Use of ionic and non-ionic cellulose ethers for producing a gel-like agent for preventing the resorption of fats from the gastro-intestinal tract
07/03/2003WO2003053450A1 Ribavirin granulate for producing coated tablets
07/03/2003WO2003053449A1 Use of 7-monohydroxyethylrutoside for the treatment of haematological disorders, particurlarly beta-thalassemia
07/03/2003WO2003053447A1 Treatment for averting or delaying premature delivery
07/03/2003WO2003053446A1 Thienopyrimidine compounds as protein tyrosine kinase inhibitors
07/03/2003WO2003053445A1 Use of desoxypeganine for treating clinical depression
07/03/2003WO2003053444A1 New use
07/03/2003WO2003053443A1 Substituted diketopiperazines as oxytocin antagonists
07/03/2003WO2003053442A1 Tempamine compositions and methods of use
07/03/2003WO2003053441A1 Substituted 2-thio-3,5-dicyano-4-phenyl-6-aminopyridines and the use of the same
07/03/2003WO2003053440A1 Medicinal composition
07/03/2003WO2003053439A1 Use of benzofuroxan derivatives as antiplatelet agents
07/03/2003WO2003053438A1 Use of anastrozole for the treatment of post-menopausal women having early breast cancer
07/03/2003WO2003053437A1 Triazoles as oxytocin antagonists
07/03/2003WO2003053436A1 Novel benzodifuranimidazoline and benzofuranimidazoline derivatives and their use for the treatment of glaucoma
07/03/2003WO2003053435A1 Broadspectrum heterocyclic substituted phenyl containing sulfonamide hiv protease inhibitors
07/03/2003WO2003053434A1 Substituted imidazolidines, method for the production thereof, use thereof as a drug or for diagnosis, and drug containing substituted imidazolidines
07/03/2003WO2003053433A1 Indolylalkylamine derivatives as 5-hydroxytryptamine-6 ligands
07/03/2003WO2003053432A1 5ht4 partial agonist pharmaceutical compositions
07/03/2003WO2003053431A2 Pharmaceutical compositions based on azetidine derivatives
07/03/2003WO2003053430A1 Drinkable preparation comprising ketoprofen and the use thereof in the simultaneous treatment of a group of animals for processes which are accompanied by fever, inflammation and/or pain
07/03/2003WO2003053429A2 2-indanylamino derivatives for the therapy of chronic pain
07/03/2003WO2003053428A1 Controlled release dosage form having improved drug release properties
07/03/2003WO2003053427A1 Use of (+)-(1s,2s)-3-(3-dimethylamino-1-ethyl-2-methyl-propyl)phenol as anti-emetic agent
07/03/2003WO2003053426A1 Methods of treating fibromyalgia syndrome, chronic fatigue syndrome and pain
07/03/2003WO2003053425A1 Treatment of neurodegenerative and cardiovascular disorders
07/03/2003WO2003053424A1 Use of a cysteine-containing substance to increase the ventilatory activity and erythropoietin production
07/03/2003WO2003053423A2 Inhibition or prevention of infection by bacteria with epa, dha or analogs
07/03/2003WO2003053422A2 Method and compositions for treating respiratory pathologies
07/03/2003WO2003053418A1 Ultrapure oral fludara formulation with a fast releasing active substance
07/03/2003WO2003053417A2 Method for making a tablet comprising a morphine type analgesic and resulting tablet
07/03/2003WO2003053416A1 Directly compressible formulations of azithromycin
07/03/2003WO2003053412A1 Stable granulates containing s-adenosylmethionne and process for the preparation thereof
07/03/2003WO2003053411A1 Pulmonary delivery of aminoglycosides
07/03/2003WO2003053409A1 Liposome composition for delivery of nucleic acid
07/03/2003WO2003053407A1 Liposomal delivery of vitamin e based compounds
07/03/2003WO2003053405A1 Method and composition for dry eye treatment
07/03/2003WO2003053402A1 Zero-order sustained released dosage forms and method of making the same
07/03/2003WO2003053401A2 Formulation and dosage form for increasing oral bioavailability of hydrophilic macromolecules
07/03/2003WO2003053400A1 Formulation & dosage form for the controlled delivery of therapeutic agents
07/03/2003WO2003053399A2 Methods for wet granulating azithromycin
07/03/2003WO2003053393A1 Cosmetic and dermatological light-protective formulations comprising hydroxybenzophenones and benzoxazole derivatives
07/03/2003WO2003053368A2 Chalcone derivatives and their use to treat diseases
07/03/2003WO2003053366A2 Pyrimidine a2b selective antagonist compounds, their synthesis and use
07/03/2003WO2003053365A2 Syn3 compositions and methods
07/03/2003WO2003053364A2 Methods and compositions in treating pain and painful disorders using 1465,1587, 2146, 2207, 32838, 336 and 52908
07/03/2003WO2003053361A2 PYRROLOPYRIMIDINE A2b SELECTIVE ANTAGONIST COMPOUNDS, THEIR SYNTHESIS AND USE
07/03/2003WO2003053360A2 Treatment of ebv and khsv infection and associated abnormal cellular proliferation
07/03/2003WO2003053358A2 Fused heterocyclic compounds and analogs thereof: modulators of nuclear hormone receptor function
07/03/2003WO2003053356A2 APOMORPHINE INHIBITORS OF AMYLOID-β (Aβ) FIBRIL FORMATION AND THEIR USE IN AMYLOIDOSIS BASED DISEASE
07/03/2003WO2003053354A2 Fused cyclic modulators of nuclear hormone receptor function
07/03/2003WO2003053353A2 Administration of vasopeptidase inhibitors to reduce pulse pressure
07/03/2003WO2003053352A2 Therapeutic compounds for treating dyslipidemic conditions
07/03/2003WO2003053350A2 Pharmaceutical compositions of orally active taxane derivatives having enhanced bioavailability
07/03/2003WO2003053348A2 Direct osmotic hydration devices
07/03/2003WO2003053347A2 Galliumcomplexes of 3-hydroxy-4-pyrones to treat mycobacterial infections
07/03/2003WO2003053346A2 Systems and methods for treating patients with processed lipoaspirate cells
07/03/2003WO2003053343A2 Novel compounds that enhance dimerization of the subunits of hiv-1 reverse transcriptase having mutations associated with resistance to nonnucleoside reverse transcriptase inhibitors
07/03/2003WO2003053336A2 Methods for the treatment of peripheral neural and vascular ailments
07/03/2003WO2003053335A2 Methods of attenuating cognitive deficits with sulfonyl fluorides
07/03/2003WO2003053331A2 Protease inhibitors
07/03/2003WO2003053330A2 Use of oxindole derivatives in the treatment of dementia related diseases, alzheimer’s disease and conditions associated with glycogen synthase kinase-3
07/03/2003WO2003053325A2 Microencapsulation of drugs by solvent exchange
07/03/2003WO2003053292A1 Vaginal delivery of drugs
07/03/2003WO2003053222A2 Methods for treating conditions, disorders, or diseases involving cell death
1 ... 5416 5417 5418 5419 5420 5421 5422 5423 5424 5425 5426 5427 5428 5429 5430 5431 5432 5433 5434 5435 5436 ... 7860